Literature DB >> 4102851

Alterations in thyroid hormone economy in patients with hydatidiform mole.

V A Galton, S H Inggar, J Jimenez-Fonseca, J M Hershman.   

Abstract

Studies of several aspects of thyroid hormone economy have been conducted in 11 patients before and after removal of a molar pregnancy. Before evacuation of the mole, all patients demonstrated moderately to greatly elevated values for thyroidal (131)I uptake, absolute iodine uptake, and serum protein-bound-(131)I. Values for serum PBI and serum thyroxine (T(4)) concentration were consistently and often greatly increased, averaging more than twice those found in normal pregnancy and three times those in normal controls. On the other hand, the maximum binding capacity of the T(4)-binding globulin (TBG) was variably affected, and ranged between the values found in normal controls and those found in normal pregnancy. Values for the absolute concentration of free T(4) in serum were, on the average, only moderately elevated, since the proportion of free T(4) was moderately low, although not as low as in normal pregnancy. Sera of patients with molar pregnancy contained high levels of thyroid stimulating activity, as assessed in the McKenzie mouse bioassay system. The stimulator displayed a more prolonged duration of action than that of TSH and did not reveal a major immunological cross-reactivity with either human or bovine TSH, differing in the latter respect from the chorionic thyrotropin of normal human placenta. Abnormalities in iodine metabolism were rapidly ameliorated after removal of the molar pregnancy, and this was associated with the disappearance from serum of the thyroid stimulator. Despite the foregoing evidence of thyroid hyperfunction and hypersecretion of T(4), patients with molar pregnancy were neither goitrous nor overtly thyrotoxic. They did display, however, high values of the urinary pigment/creatinine ratio, a possible indication of the presence of a hypermetabolic state. It is concluded that in patients with molar pregnancy, thyroid function and T(4) secretion are stimulated, often greatly so, by an unusual thyroid stimulator which is demonstrable in the blood and which is probably of molar origin. The nature of the stimulator, as well as the reasons for both the variability of the increase in TBG which occurs in molar pregnancy and the lack of frank thyrotoxicosis, remain to be clarified.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4102851      PMCID: PMC292066          DOI: 10.1172/JCI106614

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  DETERMINATION OF THYROXINE UTILIZING THE PROPERTY OF PROTEIN-BINDING.

Authors:  B E MURPHY; C J PATTEE
Journal:  J Clin Endocrinol Metab       Date:  1964-02       Impact factor: 5.958

2.  Iodine metabolism in hydatidiform mole and choriocarcinoma.

Authors:  J T DOWLING; S H INGBAR; N FREINKEL
Journal:  J Clin Endocrinol Metab       Date:  1960-01       Impact factor: 5.958

3.  The radioiodine uptake of the human thyroid in pregnancy.

Authors:  K E HALNAN
Journal:  Clin Sci       Date:  1958       Impact factor: 6.124

4.  Thyroxinebinding by serum protein in pregnancy and in the newborn.

Authors:  J ROBBINS; J H NELSON
Journal:  J Clin Invest       Date:  1958-02       Impact factor: 14.808

5.  The thyroidal uptake of stable iodine compared with the serum concentration of protein-bound iodine in normal subjects and in patients with thyroid disease.

Authors:  B A BURROWS; J F ROSS
Journal:  J Clin Endocrinol Metab       Date:  1953-11       Impact factor: 5.958

6.  Metastatic choriocarcinoma associated with hyperthyroidism.

Authors:  J D Cohen; R D Utiger
Journal:  J Clin Endocrinol Metab       Date:  1970-04       Impact factor: 5.958

7.  Further studies on a thyroid stimulating factor in crude chorionic gonadotrophin preparations and in urine.

Authors:  A Burger
Journal:  Acta Endocrinol (Copenh)       Date:  1967-08

8.  Different slopes of the dose-response curves of human and bovine TSH in the McKenzie bioassay.

Authors:  J M Hershman
Journal:  Endocrinology       Date:  1970-05       Impact factor: 4.736

9.  Urinary excretion of estrogens in women with hydatidiform mole and choriocarcinoma.

Authors:  T Brinck-Johnsen; J Solc; V A Galton
Journal:  Obstet Gynecol       Date:  1970-11       Impact factor: 7.661

10.  Extraction and characterization of a thyrotropic material from the human placenta.

Authors:  J M Hershman; W R Starnes
Journal:  J Clin Invest       Date:  1969-05       Impact factor: 14.808

View more
  8 in total

1.  Editorial: Hyperthyroidism of hydatidiform mole.

Authors: 
Journal:  Br Med J       Date:  1976-01-24

2.  Thyroid-stimulating activity and chorionic gonadotropin.

Authors:  B C Nisula; J M Ketelslegers
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

Review 3.  Euthyroid hyperthyroxinemia.

Authors:  R Rajatanavin; L E Braverman
Journal:  J Endocrinol Invest       Date:  1983-12       Impact factor: 4.256

4.  Thyrotropin-induced hyperthyroidism caused by selective pituitary resistance to thyroid hormone. A new syndrome of "inappropriate secretion of TSH".

Authors:  M C Gershengorn; B D Weintraub
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

5.  Partial target organ resistance to thyroid hormone.

Authors:  H H Bode; M Danon; B D Weintraub; F Maloof; J D Crawford
Journal:  J Clin Invest       Date:  1973-04       Impact factor: 14.808

6.  Transient non-autoimmune hyperthyroidism of early pregnancy.

Authors:  Alexander M Goldman; Jorge H Mestman
Journal:  J Thyroid Res       Date:  2011-07-15

7.  Can Pretreatment Serum Beta-hCG be Used for Predicting Thyrotoxicosis in Gestational Trophoblastic Disease?

Authors:  Uraiwan Khomphaiboonkij; Chanisorn Termsarasab
Journal:  Asian Pac J Cancer Prev       Date:  2021-11-01

8.  Case studies in hypertension: presentation with vaginal bleeding and hypertension.

Authors:  Joe Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-11       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.